Welcome to the 7th Dermatology Drug Development Summit for Inflammatory Skin Diseases
The 7th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases returns to Boston this fall. Amidst the immense range and a steady stream of the novel, topical, and systemic agents entering exciting early phases, now is the time to gain insight from other leaders in the space.
As the world’s leading and only forum committed to overcoming significant R&D hurdles and sharing best practices for advancing efficacious next-generation therapies for chronic inflammatory skin conditions, can you really afford to miss out?
With the rising demand for patient-specific and alternative treatment options, along with some first-in-class treatments in the likes of Alopecia Areata – the 6th annual meeting addresses genetic discoveries, antibody drug development, delivery strategies, and predictive and diagnostic technologies when developing safe and effective drugs for moderate-to-severe, inflammatory skin conditions.
Ensure you join this year’s 150+ expert community in-person to:
Uncover recent studies evaluating critical inflammatory and auto-immune pathways
Gain a deeper understanding of promising biologics targeting IL-13, IL-31, IL-33, versus IL-17 associated diseases.
Assess emerging efficacious targeted approaches in the plethora of conditions outside of these pathways.
Obtain clarity on novel clinically validated endpoints within the regulatory landscape for critical dermatological conditions with high unmet needs such as Hidradenitis Suppurativa, Vitiligo, Rare Disease, and Alopecia Areata.
Testimonials from the Dermatology Drug Development Summit
“A great opportunity to spend a few days with leading drug development leaders and companies that are shaping the future of dermatology” - Contract Pharmaceuticals
“High quality conference providing insights on the opportunities and challenges in dermatology drug development” – LEO Pharma
“Great list of speakers highlighting the significant new advances in inflammatory skin disease therapy” – Nocion Therapeutics
2022 Industry Leading Speaker Faculty
Lotus Mallbris
Vice President of Global Immunology Development & Medical Affairs
Eli Lilly and Company
2022 Partners:
Expertise Partners
Event Partner
Program Partners
Innovation Partners
Exhibition Partners
